🚀 VC round data is live in beta, check it out!
Terns Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Terns Pharma and similar public comparables like Biocon, Cogent Biosciences, Celcuity, Bachem and more.
Terns Pharma Overview
About Terns Pharma
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Founded
2016
HQ
Employees
59
Website
Sectors
Financials (LTM)
EV
$5B
Terns Pharma Financials
Terns Pharma reported last 12-month revenue of — and negative EBITDA of ($116M).
In the same LTM period, Terns Pharma generated — in gross profit, ($116M) in EBITDA losses, and had net loss of ($103M).
Revenue (LTM)
Terns Pharma P&L
In the most recent fiscal year, Terns Pharma reported revenue of — and EBITDA of ($110M).
Terns Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($116M) | XXX | ($110M) | XXX | XXX | XXX |
| Net Profit | ($103M) | XXX | ($96M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Terns Pharma Stock Performance
Terns Pharma has current market cap of $6B, and enterprise value of $5B.
Market Cap Evolution
Terns Pharma's stock price is $52.56.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $6B | -0.2% | XXX | XXX | XXX | $-0.83 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTerns Pharma Valuation Multiples
Terns Pharma trades at (43.7x) EV/EBITDA.
EV / Revenue (LTM)
Terns Pharma Financial Valuation Multiples
As of April 10, 2026, Terns Pharma has market cap of $6B and EV of $5B.
Equity research analysts estimate Terns Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Terns Pharma has a P/E ratio of (58.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/EBITDA | (43.7x) | XXX | (46.0x) | XXX | XXX | XXX |
| EV/EBIT | (42.6x) | XXX | (45.8x) | XXX | XXX | XXX |
| P/E | (58.9x) | XXX | (63.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (61.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Terns Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Terns Pharma Margins & Growth Rates
Terns Pharma's revenue in the last fiscal year grew by —.
Terns Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.9M for the same period.
Terns Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 18% | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Terns Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Cogent Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Celcuity | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| Centessa Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Terns Pharma M&A Activity
Terns Pharma acquired XXX companies to date.
Last acquisition by Terns Pharma was on XXXXXXXX, XXXXX. Terns Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Terns Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTerns Pharma Investment Activity
Terns Pharma invested in XXX companies to date.
Terns Pharma made its latest investment on XXXXXXXX, XXXXX. Terns Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Terns Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Terns Pharma
| When was Terns Pharma founded? | Terns Pharma was founded in 2016. |
| Where is Terns Pharma headquartered? | Terns Pharma is headquartered in United States. |
| How many employees does Terns Pharma have? | As of today, Terns Pharma has over 59 employees. |
| Who is the CEO of Terns Pharma? | Terns Pharma's CEO is Amy Burroughs. |
| Is Terns Pharma publicly listed? | Yes, Terns Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Terns Pharma? | Terns Pharma trades under TERN ticker. |
| When did Terns Pharma go public? | Terns Pharma went public in 2021. |
| Who are competitors of Terns Pharma? | Terns Pharma main competitors are Biocon, Cogent Biosciences, Celcuity, Bachem. |
| What is the current market cap of Terns Pharma? | Terns Pharma's current market cap is $6B. |
| Is Terns Pharma profitable? | No, Terns Pharma is not profitable. |
| What is the current EBITDA of Terns Pharma? | Terns Pharma has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Terns Pharma? | Current EBITDA multiple of Terns Pharma is (43.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.